EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
dc.contributor.author | Sjögreen Gleisner, Katarina | |
dc.contributor.author | Chouin, Nicolas | |
dc.contributor.author | Mínguez Gabiña, Pablo | |
dc.contributor.author | Cicone, Francesco | |
dc.contributor.author | Gnesin, Silvano | |
dc.contributor.author | Stokke, Caroline | |
dc.contributor.author | Konijnenberg, Mark | |
dc.contributor.author | Cremonesi, Marta | |
dc.contributor.author | Verburg, Frederik A. | |
dc.contributor.author | Bernhardt, Peter | |
dc.contributor.author | Eberlein, Uta | |
dc.contributor.author | Gear, Jonathan | |
dc.date.accessioned | 2022-05-04T07:25:21Z | |
dc.date.available | 2022-05-04T07:25:21Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | European Journal of Nuclear Medicine and Molecular Imaging 49 : 1778–1809 (2022) | es_ES |
dc.identifier.issn | 1619-7070 | |
dc.identifier.issn | 1619-7089 | |
dc.identifier.uri | http://hdl.handle.net/10810/56463 | |
dc.description.abstract | [EN] The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA. | es_ES |
dc.description.sponsorship | Open access funding provided by Lund University. Economic support was granted by the Swedish Cancer Society (180747, 211754Pj01H) and Mrs. Berta Kamprad's Foundation (BKS-2020-13) (Sjogreen Gleisner). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | dosimetry | es_ES |
dc.subject | Lutetium-177 | es_ES |
dc.subject | somatostatin-receptor ligands | es_ES |
dc.subject | PSMA-targeting ligands | es_ES |
dc.subject | neuroendocrine | es_ES |
dc.subject | prostate adenocarcinoma | es_ES |
dc.title | EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © The Author(s) 2022. This article is licensed under a Creative Commons Attri- bution 4.0 International License, which permits use, sharing, adapta- tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s00259-022-05727-7 | es_ES |
dc.identifier.doi | 10.1007/s00259-022-05727-7 | |
dc.departamentoes | Física aplicada I | es_ES |
dc.departamentoeu | Fisika aplikatua I | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © The Author(s) 2022. This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.